Moderna Omicron-Targeting Booster Candidates Demonstrate Superiority Over its Spikevax Booster
Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.
Phase 3 Trial of Vaxxinity’s COVID-19 Vaccine as a Heterologous Booster Advances
Vaxxinity is moving forward with research to bring its UB-612 COVID-19 vaccine to market as a mix-and-match booster to authorized vaccines.
COVID-19 Vaccine Boosters: Roadblocks, the Future, and Communicating the Benefits to Patients
“In the long run, what we will have is a virus that will become endemic in
our population," said Donald J. Alcendor, MD. "The idea of thinking we can chase variants with boosters is a failed effort. We must realize that.”
Long-COVID: How Common Is It?
The simple truth is that the long-lasting symptoms of COVID are something we should all be worried about.
Overview of SARS-CoV-2 Virus and Subvariants
Jacinda Abdul-Mutakabbir, PharmD, discusses the difference between the original SARS-CoV-2 strain and subvariant strains.
Adjuvanted Novavax Booster Adapts to New Variants
What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.
Novavax Recommended as Mix-and-Match Booster Dose After Primary COVID-19 Vaccine Series
The Novavax booster dose administered in a small study induced more robust antibody responses and its safety profile was considered favorable.
Moderna’s Bivalent COVID-19 Booster Elicits Superior Antibody Responses
Moderna’s new bivalent COVID-19 booster, which includes 25 micrograms each of messenger RNAs from the Wuhan-Hu-1 and Omicron B.1.1.529 variants of SARS-CoV-2, elicited antibody responses that were superior to those elicited by the original vaccine.
Pfizer-BioNTech Releases Early Results from Bivalent Booster Vaccine Trial
Preliminary results from a phase 2/3 trial suggest Pfizer-BioNTech’s Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine provides better protection for younger and older adults.
FDA Authorizes mRNA Bivalent Boosters for Younger Pediatric Groups
The Moderna vaccine can be administered to children as young as six years old and the Pfizer-BioNTech vaccine for kids as young as five years old.
COVID-19 Vaccines, Boosters and Prior Infection Significantly Reduce Risks
A comprehensive cohort study of COVID-19 data has reinforced the effectiveness of the various vaccines, boosters, and prior infection in protecting against infection, hospitalization and death.
COVID-19 Hospitalizations Broken Down by Vaccination Status
A recent study broke down hospitalizations associated with COVID-19 in adults between January 2021 and April of this year, based upon vaccination status.
Health Officials Urge Flu Vaccination, But Few Adults Plan to Get the Shot
The CDC is urging all eligible persons to receive a flu shot, but a new survey shows fewer adults are planning to get the vaccine this season.
CDC Finds Recovery Common From Rare Vaccine-Related Myocarditis
Largest extended study of outcomes after rare myocarditis from mRNA COVID-19 vaccines finds most recover and regain quality of life.
COVID-19 Vaccine Boosters: Safety, Efficacy, and Improving Uptake
“Vaccines are the most highly scrutinized public health interventions we know,” said Donald Alcendor, PhD.
Shionogi Reaches Endpoint for Phase 3 COVID-19 Pill
The investigational therapy demonstrated time to first resolution of the five COVID-19 symptoms was significantly reduced in those treated with low dose of medication.
Bivalent SARS-CoV-2 Vaccine Might Offer Better Omicron Protection
Interim data show a bivalent vaccine that contains the Omicron variant may be more effective.
Pfizer-BioNTech, Moderna Seek FDA EUA for Bivalent Vaccine Boosters in Pediatric Population
These vaccines target the wild strain as well as the Omicron BA.4/BA.5 variants.
Assessing Excess Mortality from COVID-19 Across US States
Investigators examined all-cause excess mortality and sought to uncouple it from COVID-19 in US states with high vaccination rates.
Gut Microbiota in Early Life May Affect Vaccine Efficacy
Bifidobacterium and Bacteroides in the gut microbiome are important to vaccine responsiveness and could be used in vaccine adjuvants in the future, a recent review shows.
European Union Authorizes Novavax Booster
The vaccine is available in adults 18 years and older.
Can Zoonotic Exposure Predict COVID-19 Prevalence?
Investigators surmise a natural bat exposure within certain areas of the world may correspond with lower COVID-19 incidence rates.
Mucosal Antibody Response to COVID-19 mRNA Vaccines Depends on Prior Infection
Injected COVID-19 mRNA vaccines alone were ineffective at producing mucosal antibody responses, according to a recent study that suggested seeking new strategies such as intranasal vaccines.
Risk of Severe COVID-19 with BA.1 and BA.2 Subvariants Low
COVID-19 disease severity was mild in individuals in Qatar infected with the Omicron BA.1 and BA.2 sublineages with vaccination and booster doses reducing risks even further, a new study showed.
Valneva Publishes Trial Results for Inactivated, Whole-Virus COVID-19 Vaccine
Valneva’s COVID-19 vaccine candidate, VLA2001, demonstrated superior virus-neutralizing antibodies compared to the AstraZeneca vaccine.
CDC Recommends mRNA Boosters
The federal agency's recommendation for both the Moderna and the Pfizer-BioNTech updated bivalent vaccines allows people to get the booster dose this fall.
FDA Authorizes mRNA Bivalent COVID-19 Vaccines as Boosters
This Emergency Use Authorization for the Moderna and Pfizer-BioNTech vaccines brings them both one step closer for people to become eligible for these boosters.
AIVITA Publishes Phase 1 and 2 Trial Results of Novel COVID-19 Vaccine
AIVITA’s COVID-19 vaccine candidate contains only the subject’s primed immune cells.
Thromboembolism After COVID-19 vs. Influenza
A new study found that patients hospitalized with COVID-19 are at significantly higher risk for venous thromboembolism in the ensuing 3 months than are patients hospitalized with influenza.
Risk of Myocarditis Higher After COVID-19 Infection Than After Vaccination
A study published this week by the American Heart Association found myocarditis was more common after COVID-19 infection than after COVID-19 vaccination.
2 Clarke Drive Cranbury, NJ 08512